Evidence map›Paper›PMID 28968743›Full record

ArticleCarcinogenesis2017

p62/SQSTM1 interacts with vimentin to enhance breast cancer metastasis.

Si-Si Li, Ling-Zhi Xu, Wei Zhou, Shang Yao, Chun-Li Wang, Jiang-Long Xia, He-Fei Wang, Muhammad Kamran, Xiao-Yuan Xue, Lin Dong and 9 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Carcinogenesis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Dichotomous role of autophagy in cancer.Asian biomedicine : research, reviews and news · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Si-Si LiCancer Center, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Ling-Zhi XuDepartment of Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Wei ZhouCancer Center, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Shang YaoDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Chun-Li WangCancer Center, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Jiang-Long XiaCancer Center, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
He-Fei WangCancer Center, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Muhammad KamranCancer Center, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Xiao-Yuan XueCancer Center, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Lin DongCancer Center, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Jing WangDepartment of Oncology, the First Affiliated Hospital of Dalian Medical University, Dalian, China.
Xu-Dong DingDepartment of Pathology, the Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Laura BellaDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Laurence BugeonDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Jie XuCancer Center, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Fei-Meng ZhengCancer Center, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Margaret J DallmanDepartment of Life Sciences, Imperial College London, London SW7 2AZ, UK.
Eric W F LamDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Quentin LiuCancer Center, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Sun Yat-sen University Cancer Center · CNImperial College London · GBDalian Medical University · CNSun Yat-sen University · CNFirst Affiliated Hospital of Dalian Medical University · CNSecond Affiliated Hospital of Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The signalling adaptor p62 is frequently overexpressed in numerous cancer types. Here, we found that p62 expression was elevated in metastatic breast cancer and its overexpression correlated with reduced metastasis- and relapse-free survival times. Analysis of p62 expression in breast cancer cell lines demonstrated that high p62 expression was associated with the invasive phenotypes of breast cancer. Indeed, silencing p62 expression attenuated the invasive phenotypes of highly metastatic cells, whereas overexpressing p62 promoted the invasion of non-metastatic cells in in vitro microfluidic model. Moreover, MDA-MB-231 cells with p62 depletion which were grown in a three-dimensional culture system exhibited a loss of invasive protrusions. Consistently, genetic ablation of p62 suppressed breast cancer metastasis in both zebrafish embryo and immunodeficient mouse models, as well as decreased tumourigenicity in vivo. To explore the molecular mechanism by which p62 promotes breast cancer invasion, we performed a co-immunoprecipitation-mass spectrometry analysis and revealed that p62 interacted with vimentin, which mediated the function of p62 in promoting breast cancer invasion. Vimentin protein expression was downregulated upon p62 suppression and upregulated with p62 overexpression in breast cancer cells. Linear regression analysis of clinical breast cancer specimens showed a positive correlation between p62 and vimentin protein expression. Together, our findings provide strong evidence that p62 functions as a tumour metastasis promoter by binding vimentin and promoting its expression. This finding might help to develop novel molecular therapeutic strategies for breast cancer metastasis treatment.

Indexed as

AnimalsBreast NeoplasmsCell Line, TumorCell MovementDown-RegulationFemaleGene Expression Regulation, NeoplasticHEK293 CellsHumansMCF-7 CellsMiceMice, Inbred BALB CMice, NudeNeoplasm InvasivenessNeoplasm MetastasisNeoplasm Recurrence, LocalSequestosome-1 ProteinSQSTM1 protein, humanVimentin

Identifiers

PMID28968743
PMCPMC5862327
OpenAlexW2754097799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.